OrbiMed’s Avita Medical RCEL Stock Holding History

OrbiMed’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40,966,100	Closed	-$154M	–	146
2026 Q1	$154M	Buy	+40,966,100	New	+$172M	3.06%	6

Other funds holding RCEL

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed's RCEL Position: Q2 2026 in Review

OrbiMed sold out of Avita Medical (RCEL) in Q2 2026, closing a stake of 544,895 shares — an estimated $42.5M sold.

OrbiMed first reported a position in RCEL in Q1 2026 and held it in 1 quarter. The position peaked at $42.5M in Q1 2026. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

OrbiMed reported no remaining Avita Medical position as of Q2 2026 after selling out during the quarter.
OrbiMed sold 544,895 Avita Medical shares in Q2 2026, an estimated $42.5M.
OrbiMed first reported a position in Avita Medical in Q1 2026 and held it in 1 quarter.
OrbiMed's Avita Medical position peaked at $42.5M in Q1 2026.
73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.